Neonatal sepsis is the leading cause of neonatal mortality in India, causing 30-40% of deaths despite medical advances. The international NeoSep1 trial has now expanded to India to test new antibiotic combinations against drug-resistant infections, aiming to save lives by identifying safe, effective, and affordable treatments tailored to local microbial profiles.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Trial Name: NeoSep1
- ›Sponsor: GARDP Foundation
- ›Target this Data: Neonatal sepsis causes 30%–40% of neonatal deaths in India, equating to 2,00,000–2,50,000 preventable deaths annually.
- ›Target this Nodal Body: GARDP Foundation (Global Antibiotic Research and Development Partnership) is the trial sponsor.
- ›Target this Legal Point: No direct legal provision; focus on scheme/initiative linkage (though none is mentioned explicitly).
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.